IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 88.7M shares rose 0.4% year over year, behind the +4.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +4.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
88.7M+0.1% QoQ
Last fiscal yearDec 2025
88.49M+8.3% YoY
LTMMar 2026
88.86M+4.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+8.3%——
3-year CAGR+28.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
88.49M USD
Year-over-year change
+8.3%
4-year CAGR
+25.9%

Weighted Avg Shares (Diluted) vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 weighted avg shares (diluted) of 88.86M shares is the 6th highest of the 9 companies compared; the peer median is 126.99M shares.
  • Its year-over-year change of +4.6% is the 8th highest of 9, against a peer median of +21.0%.
  • Over three fiscal years its annual growth of +28.8% compares with a peer median of +26.9%.
IDYA Competitors Peer median
Weighted Avg Shares (Diluted) for IDYA and competitors
Company Period LTM YoY 3-year CAGR
ERASErasca, Inc.LTM Sep 2026310.86M +9.7%+32.5%
RVMDRevolution Medicines, Inc.LTM Jun 2026197.09M +10.9%+33.1%
COGTCogent Biosciences, Inc.LTM Jun 2026160.65M +43.3%+39.9%
TNGXTango Therapeutics, Inc.LTM Sep 2026145.89M +32.5%+9.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
VSTMVerastem, Inc.LTM Mar 202682.44M +107.0%+62.5%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
Peer median (excluding IDYA) 126.99M+21.0%+26.9%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.94M50.93M23.39M7M218.71M
Cost of Revenue1.73M2.1M4.01M3.83M4.59M
Gross Profit26.22M48.83M19.38M3.17M214.12M
Gross Margin93.8%95.9%82.9%45.2%97.9%
Research & Development58.16M89.54M129.51M294.67M314.7M
Selling, General & Admin18.33M21.8M24.3M35.47M63.32M
Operating Expenses76.48M111.33M153.81M330.14M373.43M
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
EBITDA(48.04M)(56.55M)(108.95M)(270.64M)(109.11M)
EBITDA Margin-171.9%-111.0%-465.9%-3866.3%-49.9%
Operating Income(50.27M)(62.5M)(134.43M)(326.98M)(159.31M)
Operating Margin-179.9%-122.7%-574.9%-4671.1%-72.8%
Interest Income506K3.85M21.47M52.5M45.62M
Interest Expense00000
Other Income / Expenses506K3.85M21.47M52.5M45.62M
Income Before Tax(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Pre-Tax Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
Income Tax Expense00000
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (Basic)(1.41)(1.42)(1.96)(3.36)(1.28)
EPS (Diluted)(1.41)(1.42)(1.96)(3.36)(1.28)
Weighted Avg Shares35.25M41.44M57.52M81.68M88.49M
Weighted Avg Shares (Diluted)35.25M41.44M57.52M81.68M88.49M

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.